The natural alliance between the pharmaceutical industry and new technologies: IFAB welcomes the Chiesi Group

Medicine and pharmacology significantly benefit from the application of new digital tools, such as supercomputing and artificial intelligence. Chiesi group joining IFAB Foundation’s members paves the way to interesting perspectives for cutting-edge projects, able to reach ground-breaking achievements in healthcare.

Chiesi is an international biopharmaceutical group, research-oriented, that develops and markets innovative drugs in three specific areas: respiratory health, rare and ultra-rare diseases, and specialist care. To achieve its mission – improving people’s well-being and quality of life – the Group acts responsibly not only for its patients but also for the communities in which it operates and for the environment.
Having adopted the legal status of Benefit Corporation in Italy, USA and France, the effort put into generating shared value for the whole society is legally binding and the core of every single corporate decision. Since 2019, Chiesi Group is a certified B Corp and strongly aims at becoming a carbon-neutral company within 2035.

Chiesi, with over 85 years of experience, is based in Parma, works in 30 countries and has over 6.000 partners. The Group’s Research and Development is based in Parma and integrates with six other major research centers in France, the United States, Canada, China, the United Kingdom and Sweden.
For further information, please visit the website:

Previous Post
Interview to Marco Becca for the video podcast “Dialoghi di Pandora Rivista”: the importance of supercomputing
Next Post
“A perspective from industry on machine learning in Earth System science”: a panel discussion scheduled on January 18th
Stay updated on the latest IFAB events and projects.Subscribe to our monthly newsletter